Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research

AK. Deva, SD. Turner, ME. Kadin, MR. Magnusson, HM. Prince, RN. Miranda, GG. Inghirami, WP. Adams,

. 2020 ; 12 (12) : . [pub] 20201221

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001514

Grantová podpora
This work was supported by Allergan (prior to its acquisition by AbbVie), Dublin, Ireland Allergan

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma. Where implant history is known, all confirmed cases to date have occurred in patients with exposure to textured implants. There is a spectrum of disease presentation, with the most common occurring as a seroma with an indolent course. A less common presentation occurs as locally advanced or, rarely, as metastatic disease. Here we review the immunological characteristics of BIA-ALCL and potential triggers leading to its development. BIA-ALCL occurs in an inflammatory microenvironment with significant lymphocyte and plasma cell infiltration and a prominent Th1/Th17 phenotype in advanced disease. Genetic lesions affecting the JAK/STAT signaling pathway are commonly present. Proposed triggers for the development of malignancy include mechanical friction, silicone implant shell particulates, silicone leachables, and bacteria. Of these, the bacterial hypothesis has received significant attention, supported by a plausible biologic model. In this model, bacteria form an adherent biofilm in the favorable environment of the textured implant surface, producing a bacterial load that elicits a chronic inflammatory response. Bacterial antigens, primarily of Gram-negative origin, may trigger innate immunity and induce T-cell proliferation with subsequent malignant transformation in genetically susceptible individuals. Although much remains to be elucidated regarding the multifactorial origins of BIA-ALCL, future research should focus on prevention and treatment strategies, recognizing susceptible populations, and whether decreasing the risk of BIA-ALCL is possible.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001514
003      
CZ-PrNML
005      
20210126092826.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12123861 $2 doi
035    __
$a (PubMed)33371292
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Deva, Anand K $u Department of Plastic and Reconstructive Surgery, Macquarie University and the Integrated Specialist Healthcare Education and Research Foundation, Sydney, NSW 2109, Australia.
245    10
$a Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. / $c AK. Deva, SD. Turner, ME. Kadin, MR. Magnusson, HM. Prince, RN. Miranda, GG. Inghirami, WP. Adams,
520    9_
$a Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma. Where implant history is known, all confirmed cases to date have occurred in patients with exposure to textured implants. There is a spectrum of disease presentation, with the most common occurring as a seroma with an indolent course. A less common presentation occurs as locally advanced or, rarely, as metastatic disease. Here we review the immunological characteristics of BIA-ALCL and potential triggers leading to its development. BIA-ALCL occurs in an inflammatory microenvironment with significant lymphocyte and plasma cell infiltration and a prominent Th1/Th17 phenotype in advanced disease. Genetic lesions affecting the JAK/STAT signaling pathway are commonly present. Proposed triggers for the development of malignancy include mechanical friction, silicone implant shell particulates, silicone leachables, and bacteria. Of these, the bacterial hypothesis has received significant attention, supported by a plausible biologic model. In this model, bacteria form an adherent biofilm in the favorable environment of the textured implant surface, producing a bacterial load that elicits a chronic inflammatory response. Bacterial antigens, primarily of Gram-negative origin, may trigger innate immunity and induce T-cell proliferation with subsequent malignant transformation in genetically susceptible individuals. Although much remains to be elucidated regarding the multifactorial origins of BIA-ALCL, future research should focus on prevention and treatment strategies, recognizing susceptible populations, and whether decreasing the risk of BIA-ALCL is possible.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB2 1TN, UK. Senior Researcher, Šárka Pospíšilová Research Group, CEITEC, Masaryk University, 601 77 Brno, Czech Republic.
700    1_
$a Kadin, Marshall E $u Department of Dermatology, Roger Williams Medical Center, Providence, RI 02908, USA. Boston University School of Medicine, Boston, MA 02908, USA.
700    1_
$a Magnusson, Mark R $u Department of Plastic Surgery, School of Medicine, Griffith University, Southport, QLD 4222, Australia.
700    1_
$a Prince, H Miles $u Epworth Healthcare, East Melbourne, Richmond, VIC 3121, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3000, Australia.
700    1_
$a Miranda, Roberto N $u Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
700    1_
$a Inghirami, Giorgio G $u Department of Pathology, Weill Cornell Medicine, New York, NY 10065, USA.
700    1_
$a Adams, William P $u Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 12 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33371292 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092822 $b ABA008
999    __
$a ind $b bmc $g 1613911 $s 1121798
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 12 $e 20201221 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a This work was supported by Allergan (prior to its acquisition by AbbVie), Dublin, Ireland $p Allergan
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace